These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Synergistic interactions between cyclophosphamide or melphalan and VP-16 in a human rhabdomyosarcoma xenograft. Lilley ER; Rosenberg MC; Elion GB; Colvin OM; Bigner DD; Friedman HS Cancer Res; 1990 Jan; 50(2):284-7. PubMed ID: 2295068 [TBL] [Abstract][Full Text] [Related]
5. In vitro versus in vivo correlations of chemosensitivity of human medulloblastoma. Friedman HS; Schold SC; Muhlbaier LH; Bjornsson TD; Bigner DD Cancer Res; 1984 Nov; 44(11):5145-9. PubMed ID: 6488174 [TBL] [Abstract][Full Text] [Related]
6. Chemotherapy and radiation therapy of human medulloblastoma in athymic nude mice. Friedman HS; Schold SC; Varia M; Bigner DD Cancer Res; 1983 Jul; 43(7):3088-93. PubMed ID: 6850617 [TBL] [Abstract][Full Text] [Related]
8. Treatment of human glioma and medulloblastoma tumor lines in athymic mice with diaziquone and diaziquone-based drug combinations. Schold SC; Friedman HS; Bjornsson TD; Bigner DD Cancer Res; 1984 Jun; 44(6):2352-7. PubMed ID: 6722774 [TBL] [Abstract][Full Text] [Related]
9. Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice. Friedman HS; Schold SC; Bigner DD Cancer Res; 1986 Jan; 46(1):224-8. PubMed ID: 2415246 [TBL] [Abstract][Full Text] [Related]
10. Preclinical studies and clinical correlation of the effect of alkylating dose. Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059 [TBL] [Abstract][Full Text] [Related]
11. Busulfan therapy of central nervous system xenografts in athymic mice. Aaron RH; Elion GB; Colvin OM; Graham M; Keir S; Bigner DD; Friedman HS Cancer Chemother Pharmacol; 1994; 35(2):127-31. PubMed ID: 7987988 [TBL] [Abstract][Full Text] [Related]
12. Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan. Friedman HS; Dolan ME; Kaufmann SH; Colvin OM; Griffith OW; Moschel RC; Schold SC; Bigner DD; Ali-Osman F Cancer Res; 1994 Jul; 54(13):3487-93. PubMed ID: 8012971 [TBL] [Abstract][Full Text] [Related]
13. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813 [TBL] [Abstract][Full Text] [Related]
14. Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy. Griswold DP; Trader MW; Frei E; Peters WP; Wolpert MK; Laster WR Cancer Res; 1987 May; 47(9):2323-7. PubMed ID: 3567926 [TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor-alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice. Phillips PC; Levow C; Catterall M; Colvin OM; Pastan I; Brem H Cancer Res; 1994 Feb; 54(4):1008-15. PubMed ID: 8313355 [TBL] [Abstract][Full Text] [Related]
16. Acute in vivo resistance in high-dose therapy. Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940 [TBL] [Abstract][Full Text] [Related]